Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.

@article{Kruithof2005HistologicalET,
  title={Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.},
  author={E. J. Kruithof and D. Baeten and Filip Van den Bosch and Herman Mielants and Eric Maximilien Veys and Filip de Keyser},
  journal={Annals of the rheumatic diseases},
  year={2005},
  volume={64 4},
  pages={
          529-36
        }
}
OBJECTIVE To confirm and extend the immunopathological evidence of effects of infliximab on the synovium in active spondyloarthropathy. METHODS Synovial biopsies obtained in patients with spondyloarthropathy at baseline and week 12 were stained and scored by two independent observers. Two study populations were evaluated: I, a cohort of 10 patients treated with 5 mg/kg infliximab at week 0, 2, and 6, plus three placebo treated patients; and II, a pooled cohort of 20 patients fulfilling… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Differential histopathology of the synovial membrane in spondyloarthropathy subtypes and rheumatoid arthritis [ abstract ]

  • D Baeten, E Kruithof, L DeRycke, Hoffman LEA, B Vandooren, H Mielants
  • Arthritis Rheum
  • 2002

Etanercept ( Enbrel H ) inhibits radiographic progression in patients with psoriatic arthritis [ abstract ]

  • P Ory, JT Sharp, D Salonen, J Rubenstein, PJ Mease, AJ Kivitz
  • Arthritis Rheum
  • 2002

Randomised double - blind comparison of chimeric monoclonal antibody to tumor necrosis factor a ( infliximab ) versus placebo in active spondyloarthropathy

  • F VandenBosch, E Kruithof, D Baeten, A Herssens, F DeKeyser, H Mielants
  • Arthritis Rheum
  • 2002

Similar Papers

Loading similar papers…